Soft Tissue Allograft Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Amniotic Allograft, Cartilage, Collagen Allograft, Dental Allograft, Meniscus Allograft, Tendon Allograft), by Application (Dentistry, Orthopedic, Wound Care) by End-User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.77 Billion
CAGR (2026-2031)	7.03%
Fastest Growing Segment	Dentistry
Largest Market	North America
Market Size (2031)	USD 7.17 Billion

Market Overview

The Global Soft Tissue Allograft Market will grow from USD 4.77 Billion in 2025 to USD 7.17 Billion by 2031 at a 7.03% CAGR. Soft tissue allografts are biological implants derived from donated human tissue, such as tendons, ligaments, and dermis, which are processed to replace damaged structures in recipients while eliminating the need for a second surgical site. The market is primarily driven by the rising prevalence of sports-related trauma and the growing reconstructive needs of an aging population. According to the National Safety Council, in 2024, 4.4 million people were treated in emergency departments for injuries involving sports and recreational equipment. This high incidence of physical trauma significantly fuels the demand for effective repair solutions that reduce surgical time and facilitate faster patient recovery.

Despite robust demand, the market encounters a significant challenge regarding the limited supply of high-quality donor tissue. The rigorous regulatory standards required for tissue procurement and sterilization create logistical bottlenecks and increase operational costs, which restricts the availability of safe allografts. Consequently, the persistent imbalance between the scarcity of suitable donor material and the escalating clinical need serves as a primary impediment to broader market expansion and stability.

Key Market Drivers

The increasing application of acellular dermal matrices (ADMs) in breast reconstruction significantly propels market growth. Surgeons increasingly utilize these soft tissue allografts to provide structural support and improve aesthetic outcomes in implant-based procedures. ADMs allow for single-stage reconstruction, reducing the need for autologous tissue flaps and minimizing donor site morbidity. This clinical shift is heavily influenced by the consistent volume of oncological surgeries requiring tissue reinforcement. According to the American Cancer Society, in May 2025, an estimated 316,950 new cases of invasive breast cancer were projected to be diagnosed in women in the United States for the year, creating a substantial baseline demand for reconstructive solutions.

Simultaneously, the rising prevalence of diabetic foot ulcers and chronic wounds drives the adoption of amniotic and dermal allografts. These biologics are critical for treating non-healing wounds in diabetic patients, as they possess inherent growth factors that accelerate tissue regeneration. The expanding commercial success of wound care divisions within major manufacturers evidences this trend. According to Organogenesis Holdings Inc., in February 2025, the company reported that net revenue from its Advanced Wound Care products reached $453.6 million for the fiscal year 2024, representing a 12% increase year-over-year. Highlighting the broader market scale, according to Integra LifeSciences, in October 2025, the company reported third-quarter revenues of $402.1 million, underscoring the continued demand within the regenerative technology sector.

Download Free Sample Report

Key Market Challenges

The constrained supply of high-quality donor tissue represents a critical barrier to the expansion of the Global Soft Tissue Allograft Market. This scarcity arises directly from the rigorous regulatory frameworks and strict medical standards governing tissue procurement, which are necessary to ensure patient safety but severely limit the pool of eligible donors. These high compliance requirements create logistical bottlenecks and increase the operational costs associated with processing and sterilization. Consequently, the market cannot scale its inventory fast enough to meet the escalating volume of reconstructive surgeries, leading to supply shortages that physically cap market revenue and growth potential.

This disconnect between high clinical demand and low raw material availability is underscored by recent industry data highlighting the exclusivity of the donation process. According to Donate Life America, in 2024, only 3 in 1,000 people died in a manner that allowed for deceased donation, a statistic that illustrates the extreme difficulty in securing viable biological material under current medical criteria. This restricted availability prevents manufacturers from fulfilling the full scope of surgeon orders, thereby directly hampering the market’s ability to stabilize and expand despite the rising incidence of sports injuries.

Key Market Trends

The increasing substitution of synthetic mesh with biologic allografts in hernia repair is reshaping the market as surgeons prioritize reinforcement that minimizes foreign body response. Conventional synthetic meshes often lead to complications like infection and erosion, prompting a shift toward tissue matrices that support natural healing. This transition is particularly evident in complex abdominal wall reconstructions, where biologic scaffolds are utilized to reduce recurrence rates. The growing commercial success of manufacturers focusing on these biocompatible alternatives reflects this demand. According to TELA Bio, March 2025, in the 'Fourth Quarter and Full Year 2024 Financial Results', the company reported full-year 2024 revenue of $69.3 million, a 19% increase year-over-year driven by strong unit sales of its reinforced tissue matrix platform.

Simultaneously, the expansion of allograft utilization in periodontal and dental implantology is accelerating, as biological materials become standard for correcting bone defects before implant placement. Clinicians increasingly rely on human bone and soft tissue grafts for ridge augmentation and sinus lifts to ensure stable foundations for prosthetics. This rising dependence on regenerative solutions aligns with the increasing volume of tooth replacement therapies globally. According to Straumann Group, February 2025, in the 'Annual Report 2024', the company helped 6.7 million patients improve their oral health in 2024, an increase of 1.1 million from the previous year, highlighting the expanding scale of restorative interventions requiring such biomaterials.

Segmental Insights

The Dentistry segment represents the most rapidly expanding category within the Global Soft Tissue Allograft Market, driven by a significant surge in periodontal procedures and dental implant placements. This growth is largely attributed to the shift among oral surgeons toward allogenic tissue matrices, which eliminate the morbidity associated with harvesting autogenous tissue from the patient’s palate. Additionally, the increasing focus on aesthetic outcomes in oral rehabilitation supports this trend. Regulatory oversight by entities such as the US Food and Drug Administration ensures the safety and efficacy of these tissue products, further encouraging their integration into routine dental practice.

Regional Insights

North America maintains a dominant position in the global soft tissue allograft market, driven by the high prevalence of sports-related orthopedic injuries and increasing demand for dental reconstruction. The region benefits from established reimbursement policies and a robust healthcare infrastructure that facilitates widespread product adoption. Additionally, stringent safety guidelines enforced by the U.S. Food and Drug Administration foster clinician confidence in tissue-based products. The strong presence of major market players and a vast network of accredited tissue banks further secure the supply chain, ensuring consistent availability for surgical procedures.

Recent Developments

• In August 2025, BioLab Holdings received confirmation from the U.S. Food and Drug Administration's Tissue Reference Group that five of its amniotic membrane products were recognized as human cell, tissue, and cellular and tissue-based products. This regulatory milestone validated that the company's allografts, including multi-layer amnion and chorion wraps, meet specific criteria for regulation solely under section 361 of the Public Health Service Act. The recognition was expected to streamline reimbursement processes and support the clinical adoption of these soft tissue coverings. The CEO of BioLab Holdings emphasized that this achievement reinforces the company's dedication to delivering compliant and effective advanced wound care solutions.
• In November 2024, RTI Surgical announced the enrollment of the first patient in its Investigational Device Exemption clinical study, ADMIRE, to evaluate the safety and effectiveness of its Cortiva Allograft Dermis. This prospective, multi-center trial was designed to support a future pre-market approval application for the use of the acellular dermal matrix in implant-based breast reconstruction. The study involves a large cohort of patients undergoing two-stage reconstruction procedures using the pre-pectoral technique. The Chief Scientific Officer of RTI Surgical stated that this initiative underscores the company's commitment to providing clinically validated soft tissue repair options and advancing evidence-based patient care.
• In June 2024, AlloSource announced the commercial launch of its AceConnex Pre-Sutured Fascia, a novel allograft device designed specifically for hip labral reconstruction and augmentation. This product, which utilizes processed fascia lata, is the first of its kind to receive 510(k) clearance from the U.S. Food and Drug Administration. The ready-to-use graft aims to improve surgical efficiency by eliminating the need for intraoperative suturing, thereby reducing overall procedure time. The President and CEO of AlloSource highlighted that this innovation supports orthopedic surgeons by providing a consistent, high-quality solution for restoring patient mobility and effectively addressing soft tissue defects.
• In June 2024, MTF Biologics entered into an expanded partnership agreement with Centurion Therapeutics to enhance the distribution of its advanced wound care allografts. This collaboration granted Centurion exclusive rights to market and distribute a range of human tissue allografts, including placental, dermal, and adipose matrices, to hospitals and post-acute care facilities. The partnership aimed to broaden clinician access to key products such as AmnioBand and AlloPatch for treating complex wounds. The President and Chief Executive Officer of MTF Biologics noted that this strategic alliance would leverage Centurion's established sales network to deliver critical tissue-based solutions to a wider patient population.

Key Market Players

• CONMED Corporation
• XTANT MEDICAL HOLDING INC.
• ALONSOURCE GROUP
• Becton & Dickinson Co.
• Arthrex, Inc
• Integra LifeSciences Holding Corp.
• Stryker Corporation
• Institute Straumann AG
• Organogenesis Inc.
• MiMed Corporation Ltd.

By Type	By Region
Amniotic Allograft Cartilage Collagen Allograft Dental Allograft Meniscus Allograft Tendon Allograft	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Soft Tissue Allograft Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Soft Tissue Allograft Market, By Type:

• Amniotic Allograft
• Cartilage
• Collagen Allograft
• Dental Allograft
• Meniscus Allograft
• Tendon Allograft

• Soft Tissue Allograft Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE